1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Coles, M.
Bicknell, W.
Watson, A.A.
Fairlie, D.P.
Craik, D.J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
37
11064
11077
10.1021/bi972979f
9693002
Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is?
1998
10.2210/pdb1ba4/pdb
pdb_00001ba4
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
4335.852
AMYLOID BETA-PEPTIDE
ABETA
1
man
polymer
no
no
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
9606
Homo sapiens
32644
unidentified
database_2
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Other
1
0
1998-06-17
1
1
2008-03-24
1
2
2011-07-13
1
3
2022-02-16
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.process_site
Y
BNL
1998-04-07
REL
REL
LOW ENERGY, VIOLATIONS AND RMSD
50
10
NOESY
TOCSY
5.1
298
K
REFINEMENT DETAILS CAN BE FOUND IN JOURNAL CITATION ABOVE.
SIMULATED ANNEALING USING NOE DISTANCE CONSTRAINTS
BRUNGER
refinement
X-PLOR
structure solution
X-PLOR
500
Bruker
AMX-500
600
Bruker
DRX-500
750
Bruker
AMX-600
750
Bruker
DRX-750
ASP
1
n
1
ASP
1
A
ALA
2
n
2
ALA
2
A
GLU
3
n
3
GLU
3
A
PHE
4
n
4
PHE
4
A
ARG
5
n
5
ARG
5
A
HIS
6
n
6
HIS
6
A
ASP
7
n
7
ASP
7
A
SER
8
n
8
SER
8
A
GLY
9
n
9
GLY
9
A
TYR
10
n
10
TYR
10
A
GLU
11
n
11
GLU
11
A
VAL
12
n
12
VAL
12
A
HIS
13
n
13
HIS
13
A
HIS
14
n
14
HIS
14
A
GLN
15
n
15
GLN
15
A
LYS
16
n
16
LYS
16
A
LEU
17
n
17
LEU
17
A
VAL
18
n
18
VAL
18
A
PHE
19
n
19
PHE
19
A
PHE
20
n
20
PHE
20
A
ALA
21
n
21
ALA
21
A
GLU
22
n
22
GLU
22
A
ASP
23
n
23
ASP
23
A
VAL
24
n
24
VAL
24
A
GLY
25
n
25
GLY
25
A
SER
26
n
26
SER
26
A
ASN
27
n
27
ASN
27
A
LYS
28
n
28
LYS
28
A
GLY
29
n
29
GLY
29
A
ALA
30
n
30
ALA
30
A
ILE
31
n
31
ILE
31
A
ILE
32
n
32
ILE
32
A
GLY
33
n
33
GLY
33
A
LEU
34
n
34
LEU
34
A
MET
35
n
35
MET
35
A
VAL
36
n
36
VAL
36
A
GLY
37
n
37
GLY
37
A
GLY
38
n
38
GLY
38
A
VAL
39
n
39
VAL
39
A
VAL
40
n
40
VAL
40
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
PHE
4
176.64
103.89
1
A
HIS
6
38.85
35.19
1
A
GLU
11
69.64
-78.65
1
A
HIS
13
-63.42
-74.88
1
A
LYS
28
-36.60
-39.64
1
A
VAL
39
-96.83
33.60
2
A
HIS
6
38.25
29.04
3
A
PHE
4
60.67
99.03
3
A
HIS
6
-87.92
42.81
3
A
HIS
13
-115.53
65.60
4
A
PHE
4
-162.77
92.94
4
A
ARG
5
-156.78
27.74
4
A
HIS
6
-161.09
48.52
4
A
GLU
11
-166.32
-6.01
4
A
VAL
39
-92.22
33.60
5
A
PHE
4
-147.51
59.09
5
A
ASP
7
-65.45
-158.57
5
A
HIS
13
-86.62
-78.97
6
A
GLU
3
-102.90
48.06
6
A
ARG
5
52.86
72.77
6
A
HIS
6
34.25
39.35
6
A
SER
8
47.35
-160.11
6
A
TYR
10
62.22
140.21
6
A
HIS
13
-75.11
-73.52
6
A
HIS
14
-148.56
14.65
6
A
VAL
39
-91.40
31.74
7
A
ARG
5
-146.04
37.92
7
A
HIS
6
-154.47
18.18
7
A
VAL
12
-78.59
-152.41
7
A
HIS
13
-120.59
-82.88
7
A
HIS
14
-148.84
17.40
8
A
ARG
5
64.42
82.00
8
A
HIS
6
-88.85
48.97
8
A
GLU
11
62.96
107.14
8
A
HIS
13
-74.27
-73.86
8
A
HIS
14
-148.48
11.52
8
A
ASN
27
-61.60
-73.89
9
A
ALA
2
-157.33
75.32
9
A
HIS
6
-80.98
33.46
9
A
TYR
10
-157.58
-67.50
9
A
GLU
11
-168.61
-48.90
9
A
VAL
12
-74.45
-166.77
9
A
HIS
13
-61.23
-89.81
9
A
HIS
14
-154.13
2.84
9
A
ASN
27
-57.30
-71.75
10
A
GLU
3
-81.09
-105.77
10
A
PHE
4
-156.85
88.65
10
A
ARG
5
48.66
24.90
10
A
HIS
6
-113.08
-114.23
10
A
ASP
7
-75.86
33.32
10
A
SER
8
-162.47
26.16
10
A
TYR
10
-83.65
-142.00
10
A
GLU
11
-168.74
-42.39
10
A
HIS
13
-153.21
5.62
10
A
ASN
27
-58.53
-70.66
model building
X-PLOR
refinement
X-PLOR
phasing
X-PLOR
THE SOLUTION STRUCTURE OF AMYLOID BETA-PEPTIDE (1-40) IN A WATER-MICELLE ENVIRONMENT. IS THE MEMBRANE-SPANNING DOMAIN WHERE WE THINK IT IS? NMR, 10 STRUCTURES
1
Y
N
A
GLN
15
A
GLN
15
HELX_P
A
VAL
36
A
VAL
36
1
1
22
GLYCOPROTEIN
GLYCOPROTEIN, AMYLOID BETA-PEPTIDE, ALZHEIMER'S DISEASE, SDS-MICELLES
A4_HUMAN
UNP
1
1
P05067
MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPEL
QITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSE
KSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE
EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFF
YGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEA
KHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL
QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQD
EVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPV
DARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL
VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN
672
711
1BA4
1
40
P05067
A
1
1
40
1
P 1